Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Extends Review Deadline For Ilex' Clofarabine

This article was originally published in The Pink Sheet Daily

Executive Summary

Ilex submits data on 14 additional patients with acute lymphoblastic and acute myeloid leukemia to FDA, extending the user fee date by three months to Dec. 30. The company completed the original rolling NDA March 29.
Advertisement

Related Content

Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Ilex Clolar Efficacy Plus Transplant Success Is Likely Focus For Cmte. Review
Ilex Clolar Efficacy Plus Transplant Success Is Likely Focus For Cmte. Review
Genzyme Eyeing Fourth Quarter Close For Ilex Merger
Genzyme Eyeing Fourth Quarter Close For Ilex Merger
Ilex Says Clofarabine Will Go To Oncologic Advisory Committee Dec. 1
Ilex Says Clofarabine Will Go To Oncologic Advisory Committee Dec. 1
Ilex Expects Priority Review For Clofarabine; Genzyme Sees Longer Timeframe
Ilex Expects Priority Review For Clofarabine; Genzyme Sees Longer Timeframe

Topics

Advertisement
UsernamePublicRestriction

Register

PS060388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel